We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+34.92%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$237M
Cap. Flow
+$422M
Cap. Flow %
39.55%
Top 10 Hldgs %
35.09%
Holding
191
New
51
Increased
37
Reduced
12
Closed
55

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$32.6M
2
XHB icon
State Street SPDR S&P Homebuilders ETF
XHB
+$16.3M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$13.4M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$12.7M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$6.77M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$10.1M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$9.16M
3
SLRN
ACELYRIN
SLRN
+$7.92M
4
PCVX icon
Vaxcyte
PCVX
+$7.26M
5
GPCR icon
Structure Therapeutics
GPCR
+$7.07M

Sector Composition

Rank Sector Weight
1 Healthcare 31.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
51
Rocket Pharmaceuticals
RCKT
$340M
$7.18M 0.67%
239,726
-415,000
-63% -$9.16M
XENE icon
52
PUT
Xenon Pharmaceuticals
XENE
$6.06B
$7.1M 0.66%
154,089
+154,078
+1,400,709% +$5.44M
IMVT icon
53
PUT
Immunovant
IMVT
$7.93B
$6.94M 0.65%
164,700
+159,166
+2,876% +$5.86M
ICVX
54
DELISTED
Icosavax, Inc. Common Stock
ICVX
$6.93M 0.65%
+440,000
New +$4.24M
LYRA
55
DELISTED
LYRA THERAPEUTICS INC
LYRA
$6.57M 0.62%
25,088
– –
EYPT icon
56
PUT
EyePoint Inc
EYPT
$1.03B
$6.54M 0.61%
283,200
+278,713
+6,212% +$3.11M
LBPH
57
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$5.91M 0.55%
979,462
+465,361
+91% +$2.32M
JAZZ icon
58
CALL
Jazz Pharmaceuticals
JAZZ
$15.9B
$5.14M 0.48%
41,800
+41,382
+9,900% +$5.16M
CABA icon
59
Cabaletta Bio
CABA
$437M
$4.92M 0.46%
+216,620
New +$3.64M
FUSN
60
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$4.81M 0.45%
+500,000
New +$2.43M
CABA icon
61
PUT
Cabaletta Bio
CABA
$437M
$4.54M 0.43%
+200,000
New +$3.36M
RCKT icon
62
CALL
Rocket Pharmaceuticals
RCKT
$340M
$4.5M 0.42%
150,000
+148,500
+9,900% +$3.28M
PRAX icon
63
Praxis Precision Medicines
PRAX
$8.58B
$4.46M 0.42%
200,000
+50,000
+33% +$901K
CRSP icon
64
CRISPR Therapeutics
CRSP
$4.73B
$4.42M 0.41%
70,546
+40,000
+131% +$2.21M
MRNA icon
65
PUT
Moderna
MRNA
$21.8B
$4.41M 0.41%
44,300
+41,857
+1,713% +$3.52M
NVAX icon
66
PUT
Novavax
NVAX
$1.2B
$4.38M 0.41%
913,200
+901,068
+7,427% +$5.52M
MOR
67
CALL
DELISTED
MorphoSys AG American Depositary Shares
MOR
$3.96M 0.37%
+400,000
New +$2.94M
DYN icon
68
Dyne Therapeutics
DYN
$4.7B
$3.8M 0.36%
+285,900
New +$2.79M
ITOS
69
DELISTED
iTeos Therapeutics
ITOS
$3.79M 0.36%
346,471
– –
NUVL
70
PUT
DELISTED
Nuvalent
NUVL
$3.56M 0.33%
48,400
+47,877
+9,154% +$2.96M
CRNX icon
71
CALL
Crinetics Pharmaceuticals
CRNX
$8.84B
$3.56M 0.33%
100,000
+95,946
+2,367% +$2.94M
NVAX icon
72
CALL
Novavax
NVAX
$1.2B
$3.42M 0.32%
713,200
+706,068
+9,900% +$4.32M
DYN icon
73
PUT
Dyne Therapeutics
DYN
$4.7B
$3.33M 0.31%
+250,000
New +$2.44M
ABEO icon
74
Abeona Therapeutics
ABEO
$366M
$3.01M 0.28%
+600,000
New +$2.64M
EWTX icon
75
Edgewise Therapeutics
EWTX
$4.13B
$2.95M 0.28%
+270,000
New +$1.9M
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Ikarian Capital held 191 positions worth $1.07B, up 28% from $831M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Ikarian Capital deployed $422M of net new capital in Q4 2023, opening 51 new positions and adding to 37 existing holdings. Its largest new stake was argenx: 70,000 shares worth $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 32% a quarter earlier.

On the sell side, the largest reduction was Rocket Pharmaceuticals, an estimated $9.16M trimmed.

  • Ikarian Capital's largest Q4 2023 buy was argenx: 70,000 shares worth $26.5M.
  • Ikarian Capital added most to Disc Medicine in Q4 2023, an estimated $2.67M increase.
  • Ikarian Capital's biggest Q4 2023 reduction was Rocket Pharmaceuticals, cutting an estimated $9.16M.
  • Ikarian Capital fully exited Akero Therapeutics in Q4 2023, selling an estimated $10.1M.
  • Ikarian Capital's ten largest holdings make up 35% of its $1.07B portfolio in Q4 2023.
  • Ikarian Capital opened 51 new positions and closed 55 in Q4 2023.
  • Ikarian Capital's portfolio value rose 28% quarter-over-quarter to $1.07B.

Based on Ikarian Capital's 13F filing for Q4 2023, filed 14 Feb 2024.